Engineered glycomaterial implants orchestrate large-scale functional repair of brain tissue chronically after severe traumatic brain injury

Charles-François V. Latchoumane,1,2 Martha I. Betancur,3 Gregory A. Simchick,4,5 Min Kyong Sun,1,6 Rameen Forghani,1, Christopher E. Lenear,1,2, Aws Ahmed1,2, Ramya Mohankumar1, Nivedha Balaji,1 Hannah D. Mason1, Stephanie A. Archer-Hartmann7, Parastoo Azadi1, Philip V. Holmes6,6, Qun Zhao1,4,5, Ravi V. Bellamkonda3, Lohitash Karumbaiah1,2,6*  

Severe traumatic brain injury (sTBI) survivors experience permanent functional disabilities due to significant volume loss and the brain’s poor capacity to regenerate. Chondroitin sulfate glycosaminoglycans (CS-GAGs) are key regulators of growth factor signaling and neural stem cell homeostasis in the brain. However, the efficacy of engineered CS (eCS) matrices in mediating structural and functional recovery chronically after sTBI has not been investigated. We report that neurotrophic factor functionalized acellular eCS matrices implanted into the rat M1 region acutely after sTBI significantly enhanced cellular repair and gross motor function recovery when compared to controls 20 weeks after sTBI. Animals subjected to M2 region injuries followed by eCS matrix implantations demonstrated the significant recovery of “reach-to-grasp” function. This was attributed to enhanced volumetric vascularization, activity-regulated cytoskeleton (Arc) protein expression, and perilesional sensorimotor connectivity. These findings indicate that eCS matrices implanted acutely after sTBI can support complex cellular, vascular, and neuronal circuit repair chronically after sTBI.

INTRODUCTION

Severe traumatic brain injuries (sTBIs) caused by blunt force or penetrating trauma to the brain lead to extensive tissue loss and lifelong disabilities (1). Although sTBIs account for only 10% of the approximately 1.7 million TBI cases reported in the United States annually, they are responsible for over 90% of all TBI-associated costs (1). There are no effective treatments to prevent cognitive impairments and tissue loss encountered after sTBI. Neural stem cells (NSCs) have long held a privileged position in neural repair strategies for their ability to mediate neuroprotective “bystander” signaling (2). However, inadequate control over NSC differentiation and the risk of immune rejection of xenografted NSCs pose serious limitations for their clinical application (3, 4). Although autologous cell therapies could help mitigate some of these concerns (5), issues related to poor survivability of transplanted cells (6), and the risk of tumorigenesis in the case of human embryonic and pluripotent stem cells (7, 8), pose significant barriers to clinical success.

Chondroitin sulfate proteoglycans (CSPGs) are major constituents of the brain extracellular matrix (ECM) and stem cell niche (9–15). CSPG-linked sulfated CS glycosaminoglycan (CS-GAG) side chains regulate growth factor signaling (16–19), neuronal development (20), and neuroplasticity (21, 22). Fibroblast growth factor 2 (FGF2) and brain-derived neurotrophic factor (BDNF) bind with high affinity to sulfated CS chains via specific sulfation motifs that act as molecular recognition sites (23). FGF2 is expressed by NSCs and radial glial cells found in neurogenic niches of the brain (24), where it is known to promote neuroprotection (25), NSC migration and proliferation (26, 27), and neurogenesis (24, 26, 28). BDNF is an important mediator of neuroplasticity at all stages of brain development (29) and is known to promote neuroprotection (30) and functional repair of the injured brain (29, 31, 32). FGF2 and BDNF also promote angiogenesis after injury (16, 33–35) and are critical for the maintenance of oxygen perfusion and tissue viability after injury.

The development of acellular three-dimensional (3D) constructs that can potentiate cellular and functional brain repair has received much attention (18, 19, 23, 36, 37). A range of natural (38–41) and synthetic (42, 43) polymer composites, as well as natural ECM-derived biomaterials (44, 45) have been used for mediating brain tissue repair. When compared to these approaches, sulfated CS-GAGs have native functionality and sulfation motif-dependent high affinity to neurotrophic factors (18, 19, 23, 37), making them ideal materials for mediating signal transduction of neurotrophic factors and complex endogenous tissue repair chronically after sTBI. In recent studies, acutely implanted 3D CS-GAG scaffolds with and without encapsulated NSCs enhanced the efficacy of endogenous NSCs and mediated neuroprotection 4 weeks after sTBI (46). However, the chronic functional implications of acellular, neurotrophic factor functionalized engineered CS (eCS) matrix implants after sTBI have so far not been assessed. eCS matrix implants that are designed to match the composition and biophysical properties of native brain ECM present an attractive approach for the treatment of sTBI-induced tissue and functional loss.

In this study, we conducted a systematic assessment of the long-term outcomes of implanting FGF2 and BDNF-laden sulfated eCS...
Matrices in rats subjected to sTBI. We performed magnetic resonance imaging (MRI) phase gradient analyses of regional cerebral blood flow (rCBF) and tissue vascularity in conjunction with longitudinal behavioral performance and functional recovery, followed by detailed terminal immunohistochemical assessments of tissue-specific biomarkers. We also quantified activity-related cytoskeletal associated protein (Arc) expression and volumetric vasculature tracing in cleared brain tissue to localize newly formed functional clusters of neurons intra- and perilesionally in sTBI rats implanted with eCS scaffolds when compared to controls.

RESULTS

Acutely implanted eCS matrices promote chronic neuroprotection and recovery of gross motor function

To assess the chronic neuroprotective effects of neurotrophic factor–laden eCS matrix implants (fig. S1), we performed controlled cortical impact (CCI)–induced sTBI in the caudal forelimb area (CFA) in rats and implanted eCS matrices 48 hours after CCI in the lesion epicenter. We performed longitudinal assessments of motor function and MRI-based quantification of tissue volume loss and conducted terminal histological quantification of injury volume (Fig. 1A).

While general locomotion was found to be similar across all groups (fig. S2A), we observed that the performance of eCS matrix–implanted rats was found to be comparable to Sham controls, whereas sTBI rats demonstrated significant motor deficits (Fig. 1B and fig. S2B).

From results of longitudinal T2-weighted MRI at 4- and 20-week time points and lesion volume analyses (Fig. 1, C and D), as well as terminal Nissl staining of tissue and quantification at 20 weeks after sTBI (Fig. 1, E and F), we were able to detect the significantly greater tissue atrophy in the sTBI-only animals when compared to eCS matrix–implanted rats and Sham controls (Fig. 1, D and F).

These results demonstrated that eCS matrix–implanted rats exhibited tissue and motor function recovery that was comparable to Sham control group animals chronically after sTBI.

eCS matrices mediate enhanced proliferation of endogenous NSCs and neurotrophic factor expression

CS matrices have been demonstrated to promote FGF2-mediated neural progenitor homeostasis and neuroprotection 4 weeks after sTBI (17, 46). Considering these previous observations, we quantified the effects of neurotrophic factor–laden eCS matrices on the chronic maintenance of proliferating NSCs in the lesion site using Ki67 and Sox-1 biomarkers (Fig. 2, A and C) and CS-mediated FGF2 retention (Fig. 2, B, D, and E). Endogenous NSC proliferation in brain tissue from eCS matrix–implanted rats was found to be comparable to Sham controls (Fig. 2C and fig. S3, A, C, and D) but was significantly decreased in sTBI-only rats. Although a significant decrease in Ki67+ cells in tissue from eCS-treated animals was observed when compared to Sham and TBI controls (fig. S3, A, B, and E), the significantly increased percentage of Sox-1−Ki67+ cells in eCS matrix–treated animals when compared to TBI controls (Fig. 2C) suggests that NSCs do not contribute to the observed overall decrease in Ki67+ cells. These findings were further corroborated by FGF2 expression levels (Fig. 2D), which followed a similar trend to Sox-1− staining. CS56 antibody staining of implanted eCS matrices and endogenously produced CS-GAGs in the lesion site revealed no significant differences in CS56 staining between TBI and eCS groups but indicated a significantly greater CS56+ staining in both groups when compared to Sham control (Fig. 2E). Qualitative differences in locational presence of CS56+ staining were observed throughout the lesion sites in eCS and sTBI-only animals. When compared to sTBI-only animals, which predominantly demonstrated CS56+ staining only in the lesion penumbra and indicated a complete lack of cellular presence in the lesion volume, eCS matrix–treated animals indicated a uniform presence of CS56+ staining throughout the lesion volume. The CS56+ staining of eCS matrix–implanted brain tissue indicates the potential residual presence of eCS matrix along with what appears to be endogenously produced CS-GAGs/CSPGs 20 weeks after sTBI. These results suggest that eCS matrix implants might enhance NSC proliferation by facilitating the sustained expression and presence of FGF2 in the lesion site 20 weeks after sTBI.

We used laser capture microdissection (LCM) to isolate perilesional tissue labeled by rat immunoglobulin G (IgG) staining (Fig. 2F), along with any tissue present in the lesion cavity to specifically identify regional changes in expression of BDNF, FGF2, CXCL12, and CXCR4 transcripts (Fig. 2G). We identified the significant and tissue-specific increase in expression levels of transcripts encoding neuroplasticity (BDNF) and neural progenitor proliferation (FGF2) factors, along with NSC homing (CXCL12 and CXCR4) transcripts in brain tissue explanted from eCS matrix–treated animals when compared to Sham and TBI controls (Fig. 2G; >2-fold, P < 0.05). Fold differences in target gene expression in eCS matrix–implanted animals were compared to that of TBI rats after normalizing to Sham group expression levels and endogenous controls (GADPH and HPRT1).

eCS matrices promote chronic neurogenesis and neuroplasticity

Because cell proliferation, neuronal differentiation, and synaptic plasticity are indicators of normal brain tissue homeostasis (47, 48), we considered the occurrence of these processes within the lesion site as measures of functional neuronal network activity, tissue maintenance, and recovery. We quantified the presence of newly formed neurons using markers for immature/migrating neuroblasts [doublecortin-positive (DCX+)] and dividing [5-bromo-2′-deoxyuridine–positive (BrdU)] neuronal cells (Fig. 3, A and B). We found a significantly increased number of dividing cells in the eCS-implanted rats when compared to Sham and TBI groups (fig. S4, A to D). A similar trend was found for DCX+ cells (fig. S4E) and DCX+/BrdU+/DAP1+ (4′,6-diamidino-2-phenylindole–positive) colabeled cells in eCS-treated animals (Fig. 3B), demonstrating a significant increase in these markers when compared to Sham and TBI groups. These results indicate that eCS matrix implants might promote the differentiation of proliferating cells into new neurons at the lesion site up to 20 weeks after sTBI.

Because synaptic vesicle presence is indicative of functional neurons and synaptic plasticity (49), we evaluated the potential change in synaptic plasticity at the 20-week time point using antibodies against the synaptic vesicle marker synaptophysin I (Syn; fig. 3C). We observed a significant increase in Syn+ signal in both DAPI+ (P = 0.014; fig. S5, A to D) and NeuN+ cells (Fig. 3D) in eCS matrix–implanted animals when compared to Sham and TBI-only rats.

Despite a net reduction in Olig2+ cells in eCS-implanted animals (fig. S6, C and D), we observed a significantly higher percentage of
Olig2+ cells colocalized with NeuN+ cells in eCS rats when compared to those in the Sham and TBI groups (fig. S6, A to C and E). In contrast to these findings, the colocalization of NeuN+ and Olig2+ relative to DAPI+ was found to be significantly reduced in TBI rats (fig. S6, B and F) when compared to Sham and eCS matrix–implanted animals.

Together, these results suggest that despite a significant reduction in the number of neurons following sTBI, eCS matrix implants...
Fig. 2. eCS implants promote NSC proliferation and neurotrophic factor expression 20 weeks after sTBI. (A) Representative tiled images of ipsilesional hemisphere (left coronal sections) of eCS rat brain tissue; scale bar, 1 mm. (A1 to A4) Representative magnification of dashed white square shown in (C) for DAPI (A1), Sox-1 (A2), Ki67 (A3), and merged (A4); scale bar, 100 μm. (B) Representative tiled images of ipsilesional hemisphere (left coronal sections) of eCS rat brain tissue; scale bar, 1 mm. (B1 to B4) Representative magnification of dashed white square shown in (A) for DAPI (B1), CS56 (B2), FGF2 (B3), and merged (B4); scale bar, 100 μm. (C) Colocalization of Sox-1⁺ cells with Ki67⁺ cells as a percentage of Ki67⁺ cells for each treatment. Kruskal-Wallis, treatment: *P < 0.001. (D) Colocalization of FGF2⁺ cells with DAPI⁺ cells as a percentage of DAPI⁺ cells for each treatment. Kruskal-Wallis, treatment: *P < 0.05. (E) CS56⁺ percentage area for each treatment. Kruskal-Wallis, treatment: *P < 0.001. Post hoc LSD Mann-Whitney U test, *P < 0.05, **P < 0.01, and ***P < 0.001. (F) At 20-week time point, brains were flash-frozen and tissue was laser capture microdissected. Total RNA was purified and used to synthesize cDNA. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using prevalidated primers of interest for quantification of gene expression. (G) Relative expression of BDNF, FGF2, CXCL12, and CXCR4 transcripts in TBI and eCS treatment groups. Two-tailed t test, *P < 0.05, **P < 0.01, and ***P < 0.001. Graphs show means ± SEM.
promoted cell proliferation, neuronal differentiation, synaptic plasticity, and potential myelination of newly formed neurons present intra- and perilesionally.

**eCS matrix implants attenuate the chronic presence of neuroinflammatory cells**

Attenuated influx of neuroinflammatory cells chronically after sTBI could prevent prolonged tissue damage and atrophy and is a marker of a favorable tissue response after TBI (50). To mark the chronic presence of activated macrophages and reactive astrocytes that are characteristic of a neuroinflammatory cellular response to brain injury, we quantified CD68⁺-activated macrophages and glial fibrillary acidic protein–labeled (GFAP⁺) reactive astrocytes (fig. S7, A to C). We observed that eCS matrix–implanted rats had similar levels of CD68⁺ cells (fig. S7D) as Sham controls, while TBI rats showed a significant decrease in CD68⁺ cells compared to Sham and eCS matrix–implanted rats. While Sham and eCS rats showed similar GFAP⁺ expression levels, TBI rats in comparison demonstrated a significant increase in GFAP⁺ area (fig. S7E). Although the TBI animals demonstrated a significant reduction in activated macrophage response, we speculate that this is likely due to the significant tissue loss and absence of intraleisional tissue in TBI animals when compared to Sham controls and eCS-treated animals. Overall, these results suggest the prevalence of an attenuated neuroinflammatory cellular response in eCS animals 20 weeks after sTBI.

**eCS matrices enhance local vascularization and global blood flow**

Because inadequate vascularization is often responsible for the failure of implanted biomaterials (51), we investigated the extent of tissue neovascularization in eCS matrix–implanted animals when compared to controls, using collagen IV (Col-IV⁺) and rat endothelial cell antigen (Reca1⁺) markers (Fig. 4, A and B). We also used MRI phase gradient imaging of CBF as a measure of vascular function (Fig. 4, C to F).

We found a significant increase in Reca1⁺ (fig. S8D) and Col-IV⁺ (fig. S8E) expression percentage area in the eCS matrix–treated animals compared to both Sham and TBI controls. Notably, Reca1 and Col-IV colocalization was detected to be ~60% in Sham and eCS matrix–treated groups, which was significantly enhanced when compared to the TBI group (Fig. 4B).

Because a significant reduction of CBF chronically is linked to cognitive dysfunction and poor prognosis in humans with sTBI (52–56) and is also associated with the lack of neuronal activity and loss of neuronal volume in humans and rats (57, 58), we assessed CBF using MRI-based normalized phase gradient (nPG) mapping...
of identified blood vessels in the lesion (Fig. 4C). We observed a significantly enhanced overall CBF in eCS matrix–implanted rats (Fig. 4D and fig. S9; estimation statistics) when compared to Sham animals, while TBI control animals showed a statistically insignificant decrease in measured CBF. Using ipsi- and contralesional region of interest (ROI) measurements (Fig. 4E), we detected a specific increase in cortical CBF in eCS matrix–implanted rats with a significantly higher CBF detected in the contra- versus ipsilesional side (Fig. 4F). Together, these results indicate that eCS matrix–implanted rats demonstrate chronically enhanced neovascularization.
perilesionally, along with significantly enhanced CBF both contra- and ipsilesionally when compared to TBI-only controls.

**eCS matrices promote chronic forelimb-specific functional recovery and activation of activity-regulated cytoskeleton-associated protein (Arc) in RFA**

We used a skilled reach task (SRT) to investigate the circuit-specific implications of the neuroprotective, neurogenic, and angiogenic attributes of eCS matrix implants following sTBI. The SRT was used as a forelimb-specific assessment of motor recovery followed immediately by terminal volumetric imaging of activity-regulated cytoskeleton-associated protein (Arc⁰). This made it possible to assess task-specific responses following a lesion of the M2–reach-to-grasp region in the rostral forelimb area (RFA).

We found that eCS matrix–implanted rats that trained for 2 weeks on the SRT (Fig. 5A) demonstrated reach-to-grasp performance recovery from week 2 that was comparable to Sham animals and that persisted up to week 8 (Fig. 5B and fig. S10). TBI control rats showed significant forelimb functional deficits throughout the 8 weeks of testing, with a transient improvement that lasted about 3 weeks (weeks 4 to 6) before significantly worsening at week 8. The quantification of ipsi- and contralateral Arc⁰ neurons (Arc⁰/NeuN⁺ coexpression; Fig. 5C) immediately after reach-to-grasp activity showed strong activation within anterior and posterior RFA regions and low contralateral signal in Sham animals (Fig. 5D). TBI control rats, in comparison, showed little to no ipsilesional RFA activity with notable contralateral activation when compared to eCS matrix–implanted rats, which demonstrated Arc⁰ signal within the RFA lesion in addition to contralateral activation.

**Perilesional laminar recordings of multiunit activity reveal the preservation of sensorimotor responses 10 weeks after sTBI in eCS matrix–implanted rats**

We stimulated the contralateral paw using low-intensity electrical pulses to further investigate whether eCS matrix implants directly facilitated recovery of sensorimotor responses (fig. S11A). We...
evaluated the spontaneous and evoked (fig. S11, B and C) electrophysiological responses from the intact M1 and M1/S1 regions using a 32-channel laminar electrode (fig. S11D). We observed that following sTBI, a rapid response to electrical stimulation of the left paw reduced in occurrence rate and increased in time jittering in all cortical layers and in the two recording positions CFA and CFA/S1 (fig. S11E). Notably, the late response recorded in the CFA region in response to paw stimulation showed an increased delay in TBI animals (fig. S11E, left; mean jitter: 36.5 ms), which was found to be faster in eCS matrix–implanted rats (mean jitter: 15.1 ms). This effect was not detected in CFA/S1 region (fig. S11E, right). The TBI control rats also showed a sustained post-stimulation activity registered during nonstimulation recording periods when compared to the prestimulation epochs (fig. S12), which was not observed in Sham and eCS matrix–implanted rats. We also found that paw stimulation induced differential activation of the CFA/S1 and CFA motor area, with TBI control animals demonstrating a marked reduction and eCS matrix–implanted animals showing a marked increase in activation respectively. These results indicate that the response and activation of the perilesional circuitry associated with sensorimotor function of forelimb were reduced in TBI rats and partially recovered in eCS matrix–implanted rats.

**RFA-specific revascularization explains neuronal presence and behavioral performance**

We performed brain tissue clearing to specifically investigate whether vascular architecture could reveal a stronger correspondence between vasculature features (Fig. 6), neuronal presence, and behavioral performance.

Following Imaris-based vasculature tracing (Fig. 6, A and B), we observed that the anterior RFA region in eCS rats showed an increased vessel segment density (Fig. 6C) and cumulative vessel length (Fig. 6D) when compared to TBI control rats, whereas both TBI and eCS matrix–implanted animals demonstrated a marked reduction in these features compared to Sham (movies S1 to S4). We also observed that the posterior RFA showed a decreased density of vasculature in both TBI and eCS matrix–implanted animals. Notably, only three of five rats showed tissue presence in the RFAa ROI in TBI controls, whereas all animals in Sham and eCS matrix–implanted groups showed cellular and tissue presence. Tissue clearing and volumetric imaging revealed a larger propensity of tissue preservation in eCS matrix–implanted rats (movies S3 and S4) compared to TBI controls (fig. S13 and movie S2), which is consistent with lesion volume analysis obtained in Fig. 1. Using strong anion exchange (SAX) high-performance liquid chromatography (HPLC) analysis of CS sulfation profiles in brain tissue, we demonstrate that brain tissue isolated intraleSIONally from eCS matrix–implanted animals closely mimicked the CS sulfation profiles of Sham and perilesional tissue in TBI animals. These results also indicate a change in CS sulfation profile in brain tissue obtained from eCS matrix–implanted animals 4 weeks after TBI when compared to eCS matrix alone, suggesting integration and remodeling of the implanted eCS matrix (fig. S14 and table S1).

We found that the mean vessel diameters of vasculature in TBI controls and eCS matrix–implanted animals were not significantly different from those in Sham rats (Fig. 6E). However, consistent with the increased CBF observed in eCS matrix–implanted animals (Fig. 4, ~20 weeks), the distribution of both vessel length density and diameter in RFAa was enhanced in eCS matrix–implanted rats when compared to Sham and TBI controls, as shown in Q-Q plots (fig. S15, A and B).

We found a significant correlation between NeuN+ cells and vessel density (fig. S16A), and NeuN+ cells and forelimb performance (fig. S16B). The correlation between vessel density and SRT performance also returns a strong Pearson’s R value (fig. S16C), although not statistically significant. Together, these results indicate that eCS matrix implants promoted vascularization intraleSIONally (RFAa), which is strongly correlated with neuronal presence and forelimb performance in rats.

**DISCUSSION**

Parenchymal volume loss of brain tissue is highly correlated with the level of TBI severity in humans, with patients sustaining severe lesions experiencing significantly greater volume loss when compared to those who sustained mild TBIs (59). As a result, functional losses are inevitable and neuroplastic changes are limited, leaving patients with chronic and debilitating impairments (1). Studies on the intracortical implantation of brain-mimetic CS and hyaluronic acid GAG scaffolds after sTBI and stroke have demonstrated the ability to mediate complex structural and functional repair of brain tissue (38, 46, 60). The acute implantation of neurotrophic factor functionalized acellular eCS scaffolds that are compositionally similar to brain ECM could present a rational approach to mitigating the significant volume and functional losses encountered chronically after sTBI.

Using a materials design strategy that exploits the native functionality of CS, we demonstrate that neurotrophic factor–laden eCS matrix implants were neuroprotective and neurogenic and significantly enhanced the peri- and intraleSIONal presence of newly formed blood vessels chronically after sTBI when compared to controls. The role of a global reduction of CBF and hypoperfusion in chronic dysfunction and poor prognosis after sTBI is well established (53–57). Our observations correlating enhanced vascular density to neuronal presence and reach-to-grasp function recovery suggest that eCS matrix implants orchestrate complex vascular repair that directly contributes to neuronal function and task-specific recovery chronically after sTBI. These effects are likely mediated by the enhanced presence and signaling of FGF2 and BDNF, which is potentiated by CS binding of these factors as demonstrated previously (17, 60, 61). We nonetheless interpret the implications of observed rCBF increase cautiously in the absence of comparative real-time cerebral oxygenation studies.

The compensatory reorganization of the motor cortex has been observed in perilesional circuitry and the contralateral hemisphere after TBI (62–65). In our studies, the volumetric quantification of Arc+ neuronal populations following left-limb usage confirmed enhanced activity in both the perilesional and contralateral regions in TBI-only rats compared to Sham controls. eCS matrix–implanted rats showed a pattern of functional activity similar to TBI-only rats, with the added presence of intraleSIONally active neurons within the implant. Because BDNF expression is known to be regulated via autocrine signaling mechanisms (66) and could be contributing to enhanced neuroplasticity observed after brain injury (62, 63, 67), we speculate that enhanced transduction of neurotrophic factor signaling could be contributing to the observed enhancement in motor remapping (Fig. 3) and potentiation of FGF2 and BDNF expression in eCS matrix–implanted animals (60, 61, 68, 69) when compared
Our results also showed a close correspondence between Arc-dependent activation patterns and both electrophysiological response and recovery of forelimb-specific sensorimotor functions. This evidence suggests that intracortical eCS implants mediated the reorganization of neuronal circuitry, leading to chronic recovery of reach-to-grasp function after sTBI.

Subacute studies conducted 4 weeks after TBI have demonstrated the neuroprotective attributes of unmodified CS matrix implants (46). However, in light of evidence suggesting the poor prognostic implications of low BDNF levels acutely after sTBI (70), and function blocking studies demonstrating the direct role of BDNF in facilitating motor function recovery (71), strategies to enhance local signal transduction of neurotrophic factors as demonstrated in this study could offer significant therapeutic benefits.

Despite the lack of eCS matrix presence 4 weeks after TBI as determined by SAX-HPLC analysis of brain tissue, our results imply that the complex cellular and vascular repair and functional recovery observed chronically in eCS matrix–implanted animals may have...
been influenced by acutely implanted eCS matrices. Future investigations of the temporal effects of indwelling CS and eCS matrix implants on neurotrophic factor signaling will help better inform the design of more effective acellular eCS matrix implants for sTBI.

In summary, our results demonstrate that rationally designed, brain-mimetic, acellular eCS implants have native structure-function attributes required to mediate chronic tissue level repair and functional recovery after sTBI. This study opens up new avenues for the design and application of synthetic sulfated GAG constructs for brain-tissue repair and informs future investigations of neuronal connectivity and electrophysiological responsiveness between the eCS matrix–implanted tissue and perilesional cortical columns.

MATERIALS AND METHODS
Animal procedures and preparation of eCS matrix

**Animals**

Sprague-Dawley rats were obtained for the 20-week (n = 33, 7 weeks old, males only; Harlan Laboratories) and 10-week experiments (n = 21, 3 weeks old, males only; Charles River Laboratories) and randomly assigned to each treatment: control craniotomy with no injury (Sham group: 20 weeks, n = 9; 10 weeks, n = 6), CCI (TBI group: 20 weeks, n = 9; 10 weeks, n = 6), and CCI implanted with eCS scaffolds (eCS group: 20 weeks, n = 15; 10 weeks, n = 9). A custom-designed controlled cortical impactor delivered the desired impact to the M1 motor cortex (20 weeks: CFA; AP (anterior-posterior): 0.5 mm; ML (medial-lateral): 0.5 mm, relatively to bregma; 10 weeks: RFA; AP: 3.0 mm; ML: 2.5 mm, relatively to bregma) of the eCS matrix–implanted animals and TBI-only controls.

All rats were singly housed with ad libitum access to food and water and following a reverse 12-hour light cycle (light OFF, 7:00 a.m. to 7:00 p.m.; light ON, 7:00 p.m. to 7:00 a.m.) in a room maintained at 70% humidity and 23°C. All procedures on animals were approved by the Institutional Animal Care and Use Committee, and protocols were performed in accordance with the *Guide for the Care and Use of Laboratory Animals* published by the National Institutes of Health (NIH).

**Surgical procedures**

Before CCI injury, each animal was anesthetized with 5% isoflurane and buprenorphine was injected subcutaneously (0.3 mg/ml, 0.05 ml/300 g; Henry Schein). Animals were placed on a stereotaxic frame attached to a temperature-controlled heating pad (37°C) with their scalp shaved and sanitized (70% EtOH and 3% povidone-iodine). Following a sagittal incision, the periosteum was cleaned using Etch Gel (Phosphoric Acid Etching, Henry Schein), and a craniotomy was performed using a 5-mm-diameter trephine bur fitted to an electronic drill. A 3-mm CCI tip was fitted onto the pneumatic piston and positioned in contact with the surface of the dura (fully extended position) and then retracted to adjust for an impact depth of 2 mm. A severe CCI injury was induced by programming the piston speed to 2.25 m/s and a dwell time of 250 ms, resulting in an initial 3-mm-diameter injury with a depth of 2 mm. Absorbable gelatin (Gelfoam, Pfizer) was applied to the injury site, and sterile cotton swabs were used to remove excess blood. The Gelfoam was then removed, and the injury site was covered completely with a layer of 1% sterile SeaKem (Lonza) agarose. Skin flaps were sutured together, closing the wound. Triple antibiotic cream was applied on the sutured skin.

**Preparation and intralesional delivery of eCS matrix**

Injured animals were randomly selected to receive intralesional injections of eCS matrix functionalized with the neurotrophic factors FGF2 (50 μg/ml; R&D Systems, 233PB025CF) and BDNF (50 μg/ml; R&D Systems, 248DB010CF) 48 hours after sTBI. The eCS matrices were prepared using previously described methods (17, 46) (22 μl: 8 μl of 10% methacrylated CS-A-GAG; 7.58 μl of neurobasal media; 4 μl of 1% photocrosslinker Irgacure-2959; Sigma-Aldrich), loaded in a 50-μl Hamilton syringe (flitted blunt 21-gauge tight lock stainless steel needle). Because predominantly 4-O sulfated CS present in CS-A has been previously determined to bind with high affinity to FGF2 (K_D, 44 nM) and BDNF (K_D, 10 nM) (17), we incubated half (11 μl) the injection volume containing methacrylated eCS matrix with BDNF (1.21 μl) and the other half with FGF2 (1.21 μl) to saturate binding sites and to affinity immobilize neurotrophic factors. The final 22 μl of injection volume containing eCS matrix–bound BDNF and FGF2 was loaded into a Hamilton syringe and photocrosslinked before intralesional injection. The 48-hour implantation time point was chosen as it was demonstrated to improve transplantation success (72) and facilitated optimal neuroprotective outcomes after TBI (46, 72). Injections were performed after reopening the skin flaps following the above described procedure, removing the 1% agarose and positioning the syringe (angle of 32°, depth: 2 mm; speed: 2 μl/min for 10 min). Buprenorphine was administered (0.3 mg/ml, 0.05 ml/300 g; Henry Schein), and the skin was sutured back.

**Behavioral assessment of functional recovery**

Chronic functional recovery was assessed using longitudinal gross motor recovery assays including the beam-walk test (BW) (73), rotarod test (RTT) (74), and open field test (OFT) for time points corresponding to weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 after sTBI. Chronic recovery of forelimb-specific function was assessed using the SRT following preference and forced-side training at 1, 2, 4, 6, and 8 weeks after sTBI. All tasks were performed during the dark cycle in a red light lit room held at constant 70% humidity and 23°C.

**Magnetic resonance imaging**

**MRI procedure**

A 7-T Varian Magnex MRI scanner and a 35-mm dual-tuned surface coil were used to perform MRI of the brain to investigate the chronic (20 weeks) effects of sTBI. All animals were placed directly under isoflurane (1.5%) anesthesia on the holder of the animal-tube assembly, where a catheter was added to the tail of each rat intravenously with a line prefilled with 0.2 ml of heparin flush attached. The animal’s head was securely positioned directly under the 20-mm dual-tuned surface coil, and the animal-tube assembly was placed inside the 210-mm horizontal bore of the small animal scanner. For each imaging sequence, eight coronal brain slices with 1-mm thickness and zero gap between slices were acquired using a field of 40 mm × 40 mm and a matrix size of 256 × 256. The following two imaging sequences were acquired for each animal: (i) T2*-weighted fast spin echo (T2WI): TR (time repetition) = 2.0 s, TE (time echo) = 32 ms, and 4 averages requiring an acquisition time of 4 min and 20 s and (ii) T2*-weighted multigradient echo (MGEMS): TR = 600 ms, 8 echoes (TE = 10 to 45 ms in 5-ms increments), FA (flip angle) = 25°, and 4 averages requiring an acquisition time of 10 min and 14 s. Therefore, the total acquisition time for each animal was ~15 min.
**Brain tissue preparation and immunohistochemistry**

**Tissue collection at 20-week time point**
Twenty weeks after injury, animals were heavily sedated using ketamine (65 mg/kg) and transcardially perfused with 250 ml of 0.1 phosphate-buffered saline (PBS; pH 7.4). Brains were then extracted and cut in half (transversal cut), 7 mm from the apex of the frontal cortex, flash-frozen in liquid nitrogen, and stored at −80°C. Coronal sections were obtained using a Leica cryostat, starting from the center of the injury and moving caudally. A total of 48, 15-μm-thick sections were collected per animal and distributed evenly over 10 charged slides and 2 membrane slides (4 sections per slide). Two slides per animal were placed in 4% paraformaldehyde containing 4 M sucrose and stained with 0.1% cresyl violet solution to label Nissl bodies in neurons. The remaining eight charged slides were used for immunofluorescence assays, and the two membrane slides were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR).

**Injury volume determination**
As T2WI images revealed the largest areas of injury and inflammation, T2WI images were used to design an ROI library for each animal’s injured cortex using ImageJ (NIH, MD) to manually segment the injured area.

**Phase gradient mapping**
The rate of flow in a blood vessel is inversely proportional to the change in phase between the vessel and the surrounding tissue (75). However, during MR acquisition, phase measurements are only recorded in the range of ±π, and any values that extend outside of this range get “wrapped,” or forced into this range, making the change in phase difficult in areas where wrapping occurs. Because the change in phase is proportional to the change in the phase gradient, phase gradient maps (PGMs) can be used to avoid this wrapping problem (76).

Changes in rCBF between groups were determined using the T2*-weighted MGEMS data using the following procedure (77). PGMs were generated for each slice by calculating the magnitude of the phase gradients determined in the readout and phase encoding directions (76). From the PGMs, phase gradient differences between a vessel and the surrounding tissue were measured across all distinguishable vessels located within the cortex, subcortical and basal forebrain areas, and thalamus. The third echo (TE = 20 ms) was used for all measurements, as this echo produced the best contrast for distinguishing vessels within the PGMs. To account for systematic phase variations in the MRI acquisition across rats (differences in coil tuning, gradient shimming, etc.), measurements were normalized using the phase gradient difference measured across the third ventricle for each rat. Averages and SDs of all nPG differences were calculated for all vessels located on both the contralateral and ipsilateral side of the brain to the injury for each region and group.

**Quantitative RT-PCR**
Total RNA was extracted from LCM processed tissue using a PicoPure RNA Isolation kit (Thermo Fisher Scientific) and quantified using a NanoDrop analyzer (Thermo Fisher Scientific). Pooled total RNA (100 ng equivalent) (five slices per animal; seven rats) was used to synthesize complementary DNA (cDNA) using an RT First Strand kit (Qiagen). Prevalidated primers targeting rat CXCR4, CXCL12, BDNF, and FGF2, along with the housekeeping genes HPRT1 and GAPDH (Qiagen), were used in qRT-PCR assays for 40 cycles in three steps: 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min. Melting curve analysis was conducted to validate amplification specificity. All assays were conducted in triplicate on a 7900 HT instrument (Applied Biosystems), and gene expression levels were normalized to endogenous gene controls plotted as relative units using the ΔΔCt method. Gene expression was analyzed with an absolute fold difference greater than 2. Gene expression was normalized against the average expression of Sham controls.

**Tissue collection and preparation for task- and stimulation-specific activation of immediate early genes—10 weeks**
For the visualization of functional activity in the whole brain, we used antibody staining against the immediate early gene—encoded actin-regulated cytoskeleton-associated protein (Arc). Two groups of rats were used at 10 weeks after sTBI. The first cohort of rats performed a continuous 40 min of SRT (specific left forelimb activation with high repetition; n = 3 to 4 per group) before being immediately sacrificed for tissue collection. The second cohort of rats was used for intracortical recordings and perilesional electrophysiological response to the left paw stimulation (see the “Electrophysiological recordings” section; n = 3 to 4 per group) before being sacrificed for tissue collection. These two cohorts were used to map the volumetric activation of neuronal networks in relation to either volitional control of the left forelimb (SRT cohort) or the sensorimotor response to paw stimulation. All brains were collected after transcardial perfusion with 250 ml of 1X PBS containing 4% paraformaldehyde, and processed for iDisco+ tissue clearing.

**iDisco+ tissue clearing and immunostaining**
Following post-fixation, the frontal sections of the brains were treated for immunostaining and tissue clearing using the iDisco+ method (79) with steps described briefly in Table 3.

**Tissue imaging and quantification**
Brain slices were imaged using either a Leica DM IRBE (Volocity software; immunostained slices), epifluorescence Leica DM IRBE (Volocity software; cresyl/Nissl stain slices), or LaVision Ultra II Light Sheet microscope (iDisco+ cleared brains).

Image quantification for immunostained slices was performed using MATLAB and custom scripts based on the image processing toolbox. For cresyl violet–stained slices, the ROI represented 10.494 mm², and four images were taken per animal per group (n = 7, 28 total images). ImageJ (NIH, MD) was used to calculate and analyze the total number of marked Nissl bodies. Images were
thresholded to signal peak (~200). Only elements of surface area in the range 50 to 500 pixels were counted, and any noncellular bodies outside this range were removed using the subtraction tool. For volumetric images, all image stacks were converted and processed using the software Imaris (Bitplane). Nuclear counts (NeuN+ and Arc+ staining) and colocalization were performed using spot detection and spot colocalization. Vascular density (Reca1+) and orientation were performed using a batch sequence of (i) surface mapping, (ii) surface model-based masking, (iii) masked image Gaussian filter, and (iv) filament tracing (closed loop) for vasculature parameter extraction.

**eCS quantification and characterization**

**GAG isolation.** Brain tissue and eCS matrix samples were reconstituted in 2 ml of 0.1 M tris-HCl (pH 8.0) containing 2 mM CaCl2 and 1% Triton X-100. The samples were homogenized, pronase (1.6 mg) was added to bring the whole concentration up to 0.8 mg/ml, and the tissue was digested with shaking at 50°C. After 24 hours, a second 1.6-mg aliquot of pronase was added and digestion continued for 24 hours. Lastly, the enzyme was inactivated by heating to 100°C for 15 min. The buffer was adjusted to 2 mM MgCl2, benzonase (100 mU) was added, and the sample was incubated for 2 hours at 37°C. After inactivation of the enzyme (15 min, 100°C), any undigested material was removed by centrifugation for 1 hour at 4000 g. The supernatant was applied to a DEAE-Sepharose column, washed with ~10 column volumes of loading buffer (pH ~8 tris buffer, 0.1 M NaCl). The sample was then eluted in 3CVs of elution buffer (pH ~8 tris buffer, 2 M NaCl). Following lyophilization to dryness, the salt was removed with a commercial PD-10 column and then relyophilized.

**GAG lyase digestion.** All of the isolated GAG material was used for lyase digestions with chondroitinase ABC. Briefly, a solution (100-μl total volume) of each of the samples was treated with chondroitinase ABC and incubated over 16 hours (pH 8). The

| Purpose | Antibody | Manufacturer | Catalog no. | Host | Dilution | Usage |
|---------|----------|--------------|-------------|------|----------|-------|
| Neuronal presence/marker | NeuN | EMD Millipore | MAB377 | Mouse | 1:500 | Slices |
| Neuronal presence/marker | NeuN | EMD Millipore | ABN91 | Chicken | 1:500 | iDisco+ |
| Neuronal proliferation | Doublecortin (DCX) | Abcam | ab18723 | Rabbit | 1:500 | Slices |
| Myelination | Olig2 | Abcam | ab109186 | Rabbit | 1:100 | Slices |
| Neural progenitor | Sox-1 | Abcam | ab87775 | Rabbit | 1:1000 | Slices |
| Ki67 | Santa Cruz | sc-7846 | Goat | 1:500 | Slices |
| Neuroinflammation | GFAP | DAKO | z0334 | Rabbit | 1:100 | Slices |
| | CD68 | Bio-Rad | mca341R | Mouse | 1:500 | Slices |
| Growth factor presence | FGF2 | Abcam | ab8880 | Rabbit | 1:200 | Slices |
| Chondroitin sulfate GAG presence | CS56 | Sigma-Aldrich | C8035 | Mouse | 1:200 | Slices |
| Plasticity | Synapsin-1 | Abcam | ab14692 | Rabbit | 1:500 | Slices |
| Neuronal activation marker | Arc | Synaptic Systems | 156003 | Rabbit | 1:1000 | Slices/iDisco+ |
| Vasculature | RECA | Bio-Rad | MCA970R | Mouse | 1:500 | Slices/iDisco+ |
| | Col IV | Abcam | Ab19808 | Rabbit | 1:500 | Slices |

| Alexa Fluor | Host | Reactivity | Isotype | Catalog no. | Company |
|-------------|------|------------|---------|-------------|---------|
| 488 | Goat | Mouse | IgG (H+L) | A11006 | Life Technologies |
| 488 | Goat | Chicken | IgY (H+L) | A11039 | Life Technologies |
| 647 | Goat | Rabbit | IgG (H+L) | A21244 | Life Technologies |
| 488 | Donkey | Goat | IgG (H+L) | A11055 | Life Technologies |
| 594 | Goat | Mouse | IgG (H+L) | A11005 | Life Technologies |
enzyme was inactivated by heating to 100°C for 5 min. Samples were centrifuged at 14,000 rpm for 30 min before introduction to the HPLC.

**SAX-HPLC analysis of sulfated CS disaccharides.** SAX-HPLC was carried out on an Agilent system using a 4.6 mm × 250 mm Waters Spherisorb analytical column with 5-μm particle size at 25°C. Solvent A: 2.5 mM sodium phosphate, pH 3.5. Solvent B: 2.5 mM sodium phosphate, 1.2 M NaCl, pH 3.5. The gradient settings used in this analysis were chondroitin/dermatan sulfate with a flow rate of 1.0 ml/min and a 10-μl injection volume of each sample:

Detection was performed by post-column derivatization. Briefly, the eluent from the column was combined with a 1:1 mixture of 0.25 M NaOH and 1% 2-cyanoacetamide pumped at a flow rate of 1.0 ml/min and a 10-μl injection volume of each sample.

### Electrophysiological recordings

**Perilesional electrophysiological recordings**

At week 8, rats that received RFA-targeted lesion were induced and maintained under anesthesia using a ketamine/xylazine cocktail (100 mg/kg) and placed on a stereotaxic frame. Following sagittal scalp incision, a craniotomy was performed caudally to the injury (AP: 0 mm, ML: 2 to 4 mm, relatively to bregma), followed by durotommy to allow for the insertion of a 32-channel silicone probe (Neuronexus). The silicone probe was then inserted in the motor area (position1: CFA, AP: 0 mm, ML: 2.5 mm) or sensorimotor area (position2: S1, AP: 0 mm, ML: 3.5 mm) at a depth of 2 mm from the surface of the brain. All recordings were performed with a single-shank, 32-channel linear probe with 50-μm spacing between recording sites (177 mm²) and a maximum span of 1.6 mm (A1x32-6 mm-50-177-CM32, 15-μm thickness, Gen4, lot #P994). The probe reference was used as main reference, and a screw positioned above the right cerebellum was used as ground.

Neural data were digitalized and recorded at 20 kHz (unit gain) using a multichannel systems W2100 acquisition module and a wireless headstage (HS32-EXT-0.5mA, 16 bit). For spike analysis, the broadband electrophysiological data were real-time band pass–filtered (300 to 5000 Hz) and a baseline precalculated threshold was used as trigger to save spike waveforms and spike event timestamps (threshold: five SDs). All recordings were performed for 5 min following a 10-min stabilization.

**Paw electrical stimulation evoked neural activity**

Paw electrical stimulation was performed from a separate HS32-EXT-0.5mA headstage to provide isolated stimulation. The stimulating electrode was a stainless steel needle inserted in the footpad of the rat paw. Paw stimulations were performed at a fixed-intensity (50 μA), biphasic electrical pulse (1-ms phase 1) optimized to minimize recording artefacts while eliciting triggered neural response. The paw stimulations were performed at a fixed-intensity (50 μA), biphasic electrical pulse (1-ms phase 1) optimized to minimize recording artefacts while eliciting triggered neural response.

### Table 3. iDisco® tissue clearing steps.

For primary and secondary antibody concentration, please refer to Tables 1 and 2. RT, room temperature; DCM, dichloromethane; DBE, dibenzyl ether; DMSO, dimethyl sulfoxide; PBS, phosphate-buffered saline; PTx2, 0.05% Triton X-100 in 1× PBS; PTwh, 0.0.5% Tween 20, 0.5 ml of heparin (10 mg/ml) in 1× PBS.

| Process | Condition | Reagent | Solvent |
|---------|-----------|---------|---------|
| Initial wash | 15 min 3x in each | PTx2 and PTwh | 1× PBS |
| Serial dehydration | 1 hour each | 20/40/60/80/100% methanol | 1× PBS |
| Defatting | Overnight | DCM (66%, v/v) | Methanol |
| Bleaching | Overnight | H_2O_2 (5%, v/v) | Methanol |
| Serial rehydration | 1 hour each | 20/40/60/80/100% PBS | Methanol |
| Permeabilization | 4 days | Triton X-100, 20% DMSO | 1× PBS |
| Blocking | 2 days | Goat serum (6%, v/v) and DMSO (10%, v/v) | PTx2 |
| Primary antibody incubation | 7 days, 37°C, 100 rpm | Goat serum (3%, v/v) and DMSO (5%, v/v) | PTx2 |
| Wash | Overnight | PTwh |
| Secondary antibody incubation | 6 days, 37°C, 100 rpm | Goat serum (3%, v/v) and DMSO (5%, v/v) | PTx2 |
| Final dehydration | 1 hour each | 20/40/60/80/100% methanol | D H_2O |
| Defatting | 3 hour, RT | DCM (66%, v/v) | Methanol |
| Defatting | Overnight | DCM 100% | DCM |
| Final defatting/clearing | 30 min—hold indefinitely | 100% DBE | DBE |

| Time (min) | %A | %B |
|------------|----|----|
| 0          | 97 | 3  |
| 10         | 80 | 20 |
| 30         | 75 | 25 |
| 55         | 0  | 100|
| 65         | 0  | 100|
stimulation pulses were repeated 120 times at a frequency of 1 Hz. Each stimulation was monitored using a light-emitting diode (LED) output through a synchronized TTL port to the recording system.

Statistical analysis
All statistical analyses were performed using SigmaPlot (SyStat Software Inc., CA) or MATLAB statistical toolbox (MathWorks Inc.). For multiple group comparison (e.g., immunohistochemistry quantifications, volume, or area quantification), we used a one-way analysis of variance (ANOVA) followed by a multiple comparison least significant difference (LSD) due to the low number of group (three groups, Sham, TBI, and eCS). For group comparison on the nPG analysis (MRI), we used a three-way ANOVA followed by multiple comparison using the LSD approach. For behavior data, we performed two-way repeated-measures ANOVA using between-factor group (three levels: Sham, TBI, and eCS) and within-factor time with a post hoc multiple comparison based on the LSD. When necessary (failure of normality of sample distribution), nonparametric tests such as Kruskal-Wallis and Mann-Whitney U rank sum test were used in place of one-way ANOVA and t tests. For distribution comparisons, the measure of effect size (MATLAB toolbox, dabez estimation statistics) (80) was used to avoid bias due to high sample number as well as quartile-quartile plot against Sham distribution. For all tests, P < 0.05 was considered significant.

SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/7/10/eabe0207/DC1

View/request a protocol for this paper from Bio-protocol.

REFERENCES AND NOTES
1. V. G. Coronado, L. C. McGuire, M. Faul, D. Sugerman, W. Pearson, The epidemiology and prevention of TBI. Brain Injury Med., 45–56 (2012).
2. S. Pluchino, L. Zanotti, B. Rossi, E. Brambilla, L. Ottoboni, G. Salani, M. Martinello, A. Cattalini, A. Bergami, R. Furlan, G. Corin, G. Constamint, G. Martino, Neuronsphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436, 266–271 (2005).
3. E. W. Baker, H. A. Kindler, F. D. West, Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function. Brain Behav. 9, e01214 (2019).
4. A. Wennersten, X. Meijer, S. Holmin, L. Wahlberg, T. Mathiesen, Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injury. J. Neurosurg. 100, 88–96 (2004).
5. G. P. Liao, M. T. Harting, R. A. Hetz, P. A. Walker, S. K. Shah, C. J. Corkins, T. G. Hughes, F. Jimenez, S. C. Kosmach, M. C. Day, K. J. Tsao, D. A. Lee, L. L. Worth, J. E. Baumgartner, C. S. Cox Jr., Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr. Crit. Care Med. 16, 245–255 (2015).
6. S. C. Berman, C. Galpaththawa, A. A. Gild, J. W. Bulte, P. Walczak, Long-term MR cell tracking of neural stem cells grafted in immunocompetent versus immunodeficient mice reveals distinct differences in contrast between live and dead cells. Magn. Reson. Med. 65, 564–574 (2011).
7. J. Y. Li, N. S. Christophersons, V. Hall, D. Soulet, P. Brundin, Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 31, 146–153 (2008).
8. A. S. Lee, C. Tang, M. S. Rao, I. L. Weissman, J. C. Wu, Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Annu. Rev. Cell Dev. Biol. 4, 229–255 (1988).
9. S. Sirko, K. Akitaka, A. von Holst, A. Faissner, Structural and functional analysis of chondroitin sulfate proteoglycans in the neural stem cell niche. Methods Enzymol. 479, 37–71 (2010).
10. S. Sirko, A. von Holst, A. Weber, A. Wizenmann, U. Theecharidis, M. Götz, A. Faissner, Chondroitin sulfates are required for fibroblast growth factor-2-dependent proliferation and maintenance in neural stem cells and for epidural growth factor-dependent migration of their progeny. Stem Cells 28, 775–787 (2010).
11. S. Sirko, A. von Holst, A. Wizenmann, M. Götz, A. Faissner, Chondroitin sulfate glycosaminoglycans control proliferation, radial glia cell differentiation and neurogenesis in neural stem/progenitor cells. Development 134, 2727–2738 (2007).
12. V. G. Coronado, L. C. McGuire, M. Faul, D. Sugerman, W. Pearson, The epidemiology and prevention of TBI. Brain Injury Med., 998–1004 (2013).
13. E. Ruoslahti, Structure and biology of proteoglycans. Annu. Rev. Cell Dev. Biol. 6, 39–63 (1990).
14. S. Pluchino, L. Zanotti, B. Rossi, E. Brambilla, L. Ottoboni, G. Salani, M. Martinello, A. Cattalini, A. Bergami, R. Furlan, G. Corin, G. Constamint, G. Martino, Neuronsphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436, 266–271 (2005).
15. E. W. Baker, H. A. Kindler, F. D. West, Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function. Brain Behav. 9, e01214 (2019).
16. A. Wennersten, X. Meijer, S. Holmin, L. Wahlberg, T. Mathiesen, Proliferation, migration, and differentiation of human neural stem/progenitor cells after transplantation into a rat model of traumatic brain injury. J. Neurosurg. 100, 88–96 (2004).
17. S. Yoshimura, T. Teramoto, M. J. Whalen, M. C. Irizarry, K. Sugahara, A simple role for BDNF in learning and memory? Front. Mol. Neurosci. 3, 1 (2010).
18. S. Yoshimura, T. Teramoto, M. J. Whalen, M. C. Irizarry, K. Sugahara, A simple role for BDNF in learning and memory? Front. Mol. Neurosci. 3, 1 (2010).
19. C. Cunha, R. Brambilla, K. L. Thomas, A simple role for BDNF in learning and memory? Front. Mol. Neurosci. 3, 1 (2010).
20. A. Chen, L. J. Xiong, Y. Tong, M. Mao, The neuroprotective role of BDNF in hypoxic ischemic brain injury. Biomed. Rep. 1, 167–176 (2013).
21. G. S. Griesbach, D. A. Hovda, R. Molteni, A. Wu, F. Gomez-Pinilla, Voluntary exercise following traumatic brain injury: Brain-derived neurotrophic factor upregulation and recovery of function. Neuroscience 125, 129–139 (2004).
22. W. Xuan, T. Agrawal, L. Huang, G. K. Gupta, M. R. Hamblin, Low-level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF) and synaptogenesis. J. Biophotonic 8, 502–511 (2015).
23. H. Chu, J. Gao, C. W. Chen, J. Huard, Y. Wang, Injectable fibroblast growth factor-2 coencapsulates for persistent angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 108, 13444–13449 (2011).
24. A. Y. Fouda, A. Alhusban, T. Ishrat, B. Pillai, W. Eldahshan, J. L. Waller, A. Ergul, S. C. Fagan, Brain-derived neurotrophic factor knockdown blocks the angiogenic and protective effects of angiotensin modulation in situ experimental stroke. Mol. Neurobiol. 54, 661–670 (2017).
25. P. Kermani, B. Hempstead, BDNF Actions in the cardiovascular system: Roles in development, adulthood and response to injury. Front. Physiol. 10, 453 (2019).
26. M. Modo, S. F. Badyak, A roadmap for promoting endogenous in situ tissue restoration using inductive bioinsuflccs after acute brain injury. Brain Res. Bull. 150, 136–149 (2019).
37. S. Mizumoto, D. Fongmoon, K. Sugahara, Interaction of chondroitin sulfate and dermatan sulfate from various biological sources with heparin-binding growth factors and cytokines. Glycoconj. J. 30, 619–632 (2013).
38. L. R. Nih, S. Gojgini, S. T. Carmichael, T. Segura, Dual-function injectable angiogenic biomaterial for the repair of brain tissue following stroke. Nat. Mater. 17, 642–651 (2018).
39. M. C. Tate, D. A. Shear, S. W. Hoffman, D. G. Stein, M. C. LaPlaca, Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 22, 1113–1123 (2001).
40. W. M. Tian, S. P. Hou, J. Ma, C. L. Zhang, Q. Y. Xu, I. S. Lee, H. D. Li, M. Spector, F. Z. Cui, Hyaluronic acid-poly-D-lysine-based three-dimensional hydrogel for traumatic brain injury. Tissue Eng. 11, 513–525 (2005).
41. P. Hao, H. Duan, F. Hao, L. Chen, M. Sun, K. S. Fan, Y. E. Sun, D. Williams, Z. Yang, X. Li, Neural repair by NT3-chitosan via enhancement of endogenous neurogenesis after adult focal aspinal trauma brain injury. Biomaterials 140, 88–102 (2017).
42. C. Martínez-Ramos, U. Gómez-Pinedo, J. M. Soria, J. A. Barcia, M. M. Pradas, Neural tissue regeneration in experimental brain injury model with channeled scaffolds of acrylate copolymers. Neurosci. Lett. 598, 96–101 (2015).
43. L. Zhou, J. Tu, G. Fang, L. Deng, X. Gao, K. Guo, J. Kong, J. Li, W. Guan, C. Yang, Combining PLGA scaffold and MSCs for brain tissue engineering: A potential tool for treatment of brain injury. Stem Cells Int. 2018, 1–8 (2018).
44. K. F. Huang, W.-C. Hsu, W.-T. Chu, J.-Y. Wang, Functional improvement and neurogenesis after collagen-GAG matrix implantation into surgical brain trauma. Biomaterials 33, 2067–2075 (2012).
45. L. Zhang, F. Zhang, Z. Weng, B. N. Brown, H. Yan, X. M. Ma, P. S. Vosler, S. B. Fadlyak, C. E. Dixon, X. T. Cui, J. Chen, Effect of an inducible hydrogel composed of urinary bladder matrix upon functional recovery following traumatic brain injury. Tissue Eng. Part A 19, 1909–1918 (2013).
46. M. I. Betancur, H. D. Mason, M. Alvarado-Velez, P. V. Holmes, R. V. Bellakmonda, L. Karumbaib, Chondroitin sulfate glycosaminoglycan matrices promote neural stem cell maintenance and neuroprotection post-traumatic brain injury. ACS Biomater. Sci. Eng. 3, 420–430 (2017).
47. P. A. Walker, S. K. Shah, M. T. Harting, C. S. Cox Jr., Progenitor cell therapies for traumatic brain injury: Barriers and opportunities in translation. Dis. Model. Mech. 2, 23–38 (2009).
48. L. R. Nih, S. T. Carmichael, T. Segura, Hydrogels for brain repair after stroke: An emerging treatment option. Curr. Opin. Biotechnol. 40, 155–163 (2016).
49. R. Janz, T. C. Südhof, R. E. Hammer, V. Unni, S. A. Siegelbaum, V. Y. Bolshakov, Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 24, 687–700 (1999).
50. A. Kumar, D. J. Loane, Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. Brain Behav. Immun. 26, 1191–1201 (2012).
51. J. J. Moon, J. E. Saik, R. A. Poché, J. E. Leslie-Barbick, S. H. Lee, A. A. Smith, M. E. Dickinson, J. L. West, Biomimetic hydrogels with pro-angiogenic properties. Biomaterials 31, 3840–3847 (2010).
52. G. Goldenberg, W. Oder, J. Spatt, I. Podreka, Cerebral correlates of disturbed executive function and memory in survivors of severe closed head injury: A SPECT study. J. Neural Neurosurg. Psychiatry 55, 362–368 (1992).
53. M. Ichise, D. G. Chung, P. Wang, G. Wortzman, B. G. Gray, W. Franks, Technetium-99m-HMPAO SPECT, CT and MRI in the evaluation of patients with chronic traumatic brain injury: Imaging and cerebral 99mTc HM-PAO-SPECT in patients with subacute or chronic severe TBI. J. Neurotrauma 14, 420–430 (2017).
54. W. Oder, G. Goldenberg, J. Spatt, I. Podreka, H. Binder, L. Deecke, Behavioural and psychosocial sequelae of severe closed head injury and regional cerebral blood flow: A SPECT study. J. Neural Neurosurg. Psychiatry 55, 475–480 (1992).
55. L. Prayer, D. Wimmerber, W. Oder, J. Kramer, E. Schindler, I. Podreka, H. Imhof, Cranial MR imaging and cerebral 99mTc HM-PAO-SPECT in patients with subacute or chronic severe closed head injury and normal CT examinations. Acta Radiol. 34, 593–599 (1993).
56. Y. Inoue, T. Shiozaki, O. Tasaki, T. Hayakata, H. Ikegawa, K. Yoshiya, T. Fujimaka, H. Tanaka, T. Shimazu, H. Sugimoto, Changes in cerebral blood flow from the acute to the chronic phase of severe head injury. J. Neurotrauma 22, 1411–1418 (2005).
57. J. Kim, J. Whyte, S. Patel, B. Avants, E. Europa, J. Wang, J. Slattery, J. C. Gee, H. B. Coslett, D. A. Shear, C. C. Tate, M. C. Tate, D. R. Archer, M. C. LaPlaca, D. G. Stein, D. L. Dunbar, Stem cell survival and functional outcome after traumatic brain injury is dependent on transplant timing and location. Restor. Neural. Neurosci. 29, 215–225 (2011).
58. S. T. Fujimoto, L. Longhi, K. E. Saatman, V. Conte, N. Stocchetti, T. McIntosh, Motor and cognitive function evaluation following experimental traumatic brain injury. Neurosci. Biobehav. Rev. 38, 365–378 (2004).
59. R. J. Hamm, B. R. Pike, D. M. O’Dell, B. G. Lyeth, L. W. Jenkins, The rotarod test: An evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J. Neurotrauma 11, 187–196 (1994).
60. Y. Shen, Z. Kou, C. W. Kreipe, T. Petrov, J. H. E. Maacke, In vivo measurement of tissue damage, oxygen saturation changes and blood flow changes after experimental traumatic brain injury in rats using susceptibility weighted imaging. Magn. Reson. Imaging 25, 219–227 (2007).
61. L. Wang, W. M. Potter, Q. Zhao, In vivo quantification of SPION nanoparticles for cell labeling based on MR phase gradient images. Contrast Media Mol. Imaging 10, 43–50 (2015).
62. G. Simich, M. Betancur, L. Karumbaiah, Q. Zhao, Gauging the effectiveness of traumatic brain injury treatment using MR phase gradient mapping, in Proceedings of the 24th Annual Meeting of ISMRM, Singapore, Singapore (2016).
63. L. Karumbaiah, S. E. Norman, N. B. Rajan, S. Anand, T. Saxena, M. Betancur, R. Patkar, R. V. Bellakmonda, The upregulation of specific interleukin (IL) receptor antagonists and paradoxical enhancement of neuronal apoptosis due to electrode induced brain and chronic brain micromotion. Biomaterials 33, 5983–5996 (2012).
64. N. Renier, Z. Wu, D. J. Simon, Y. Pang, A. M. M. Tisser-Pavon, DISCO: A simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896–910 (2014).
65. J. H. O. Tumakay, S. Aryan, H. Choi, A. Claridge-Chang, Moving beyond P values: Data analysis with estimation graphics. Nat. Methods 16, 565–566 (2019).

Acknowledgments: We thank C.-J. Tsai (UGA Department of Genetics) for providing us access to the Leica laser capture microdissection microscope and S. GC (UC Irvine) for insightful technical discussions. We also acknowledge technical assistance from M. Logun on preliminary surgeries and behavioral testing. Funding: This work was supported by an NIH (RO1NS099996) award to L.K. and partially supported by a Georgia Partners in Regenerative Medicine seed grant from the Regenerative Engineering and Medicine (REEM) research center to R.V.B. and L.K. and an Alliance for Regenerative Rehabilitation Research and Training (AT3T).
technology development grant to L.K. and C.-F.V.L. P.A. acknowledges NIH support (R24GM137782) for this work. **Author contributions:** C.-F.V.L., M.I.B., and L.K. designed experiments. C.-F.V.L., M.I.B., H.D.M., R.F., and M.K.S. performed all animal behavior experiments and surgeries. N.B. and L.K. performed LCM and qRT-PCR experiments. M.I.B. performed MRI imaging, and G.A.S. performed phase gradient analysis. C.-F.V.L., M.K.S., and A.A. performed the tissue clearing, volumetric imaging, and volumetric quantification. C.-F.V.L. and R.F. performed the electrophysiological recording. C.-F.V.L., M.K.S., R.F., N.B., and C.E.L. performed cryosectioning, staining, and imaging of all samples. C.-F.V.L., R.M., and N.B. performed immunohistochemistry-based quantification, behavior analysis, qRT-PCR analysis, and statistical analysis. S.A.A.-H. performed SAX-HPLC. S.A.A.-H. and P.A. analyzed SAX-HPLC data. C.-F.V.L., Q.Z., P.V.H., R.V.B., and L.K. wrote and edited the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Data can be obtained on demand by contacting the corresponding author: Lohitash@uga.edu.

Submitted 27 July 2020
Accepted 21 January 2021
Published 5 March 2021
10.1126/sciadv.abe0207

**Citation:** C.-F. V. Latchoumane, M. I. Betancur, G. A. Simchick, M. K. Sun, R. Forghani, C. E. Lenear, A. Ahmed, R. Mohankumar, N. Balaji, H. D. Mason, S. A. Archer-Hartmann, P. Azadi, P. V. Holmes, Q. Zhao, R. V. Bellamkonda, L. Karumbaiah, Engineered glycomaterial implants orchestrate large-scale functional repair of brain tissue chronically after severe traumatic brain injury. Sci. Adv. 7, eabe0207 (2021).